We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02070471
Recruitment Status : Completed
First Posted : February 25, 2014
Last Update Posted : May 10, 2016
Sponsor:
Information provided by (Responsible Party):

February 21, 2014
February 25, 2014
May 10, 2016
January 2014
June 2015   (Final data collection date for primary outcome measure)
AUC of CK-MB for 72 hours post PCI [ Time Frame: pre PCI, PCI 0h, 6h, 12h, 18h, 24h, 48h, 72h ]
Same as current
Complete list of historical versions of study NCT02070471 on ClinicalTrials.gov Archive Site
  • AUC of Troponin I and CK for 72h post PCI [ Time Frame: pre PCI, PCI 0h, 6h, 12h, 18h, 24h, 48h, 72h ]
  • Infarct size and myocardial function assessed by CMR and Echocardiogram [ Time Frame: Day 4, 30 ]
Same as current
Not Provided
Not Provided
 
Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Single Injection LC28-0126 Immediately Before PCI (Percutaneous Coronary Intervention) in Patients With STEMI(ST-segment Elevation Myocardial Infarction)
Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before PCI (Percutaneous Coronary Intervention) in Patients with STEMI (ST-segment Elevation Myocardial Infarction)
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
ST-segment Elevation Myocardial Infarction
  • Drug: Placebo
    Placebo
  • Drug: LC28-0126 Dose A
    LC28-0126 Dose A
  • Drug: LC28-0126 Dose B
    LC28-0126 Dose B
  • Drug: LC28-0126 Dose C
    LC28-0126 Dose C
  • Experimental: LC28-0126 Dose A
    LC28-0126 Dose A
    Intervention: Drug: LC28-0126 Dose A
  • Experimental: LC28-0126 Dose B
    LC28-0126 Dose B
    Intervention: Drug: LC28-0126 Dose B
  • Experimental: LC28-0126 Dose C
    LC28-0126 Dose C
    Intervention: Drug: LC28-0126 Dose C
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
Not Provided
June 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age between 20 and 75
  • Within 12 hours after the onset of chest pain
  • ST-segment elevation of more than 0.1 mV in two contiguous leads or new LBBB(left bundle-branch block) patients
  • Signed for written informed consent

Exclusion Criteria:

  • Left Main disease
  • Multi-vessel disease
Sexes Eligible for Study: All
20 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT02070471
LG-CYCL002
Not Provided
Not Provided
Not Provided
LG Life Sciences
LG Life Sciences
Not Provided
Not Provided
LG Life Sciences
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP